VistaGen Therapeutics, Inc. Gross Profit

Gross Profit of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Profit growth rates and interactive chart. Gross profit is a company's net sales revenue minus its cost of goods sold (or cost of revenue). In other words, it is the sales revenue a company retains after incurring the direct costs associated with producing the goods it sells, and the services it provides.


Highlights and Quick Summary

  • Gross Profit for the quarter ending December 30, 2020 was $314 Thousand (a -6.11% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Profit decreased by -1329.8%
  • Annual Gross Profit for 2020 was $-103 Thousand (a 13.05% increase from previous year)
  • Annual Gross Profit for 2019 was $-91.2 Thousand (a 13.01% increase from previous year)
  • Annual Gross Profit for 2018 was $-80.7 Thousand (a -106.46% decrease from previous year)
  • Twelve month Gross Profit ending December 30, 2020 was $597 Thousand (a 131.64% increase compared to previous quarter)
  • Twelve month trailing Gross Profit decreased by -57.36% year-over-year
Trailing Gross Profit for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$597 Thousand $258 Thousand $1.17 Million $1.4 Million
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Profit of VistaGen Therapeutics, Inc.

Most recent Gross Profitof VTGN including historical data for past 10 years.

Interactive Chart of Gross Profit of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. Gross Profit for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.31 $0.33 $-0.03 $-0.03 $-0.1
2019 $-0.03 $-0.09
2018 $-0.08
2017 $1.25
2016 $1.25 $-0.05
2013 $0.2
2012 $0.2 $0.47 $1.34
2011 $0.0 $0.32 $0.55 $0.35 $2.07
2010 $0.4 $0.73

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.